Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Aug 21:2017:bcr2017221347.
doi: 10.1136/bcr-2017-221347.

Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus

Zachary Junga  1 , Rodger Stitt  2 , Christopher Tracy  2 , Michael Keith  2
Affiliations
Case Reports

Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus

Zachary Junga et al. BMJ Case Rep. .

Abstract

Macrophage activation syndrome (MAS) is a rare disease characterised by aberrant immune hyperactivation of T lymphocytes and macrophages driven by cytokine dysfunction. The HLH-2004 protocol is commonly used for the treatment of MAS, but significant toxicities are associated. We describe a case of MAS secondary to systemic lupus erythematosus in a young female that responded well to rituximab in lieu of etoposide. She continues to be in remission 1 year following the completion of rituximab infusion and is maintained on hydroxychloroquine. This case highlights the need for further research on the use of rituximab and other available biologics in the setting of MAS in order to help guide further alternative treatment decisions.

Keywords: biological agents; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Ferritin (ng/mL) level over time from initial diagnosis to remission.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ravelli A, Minoia F, Davì S, et al. . Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American College of Rheumatology/Paediatric Rheumatology international trials organisation collaborative initiative. Arthritis Rheumatol 2016;;68:566–76. 10.1002/art.39332 - DOI - PubMed
    1. Henter JI, Horne A, Aricó M, et al. . HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124–31. 10.1002/pbc.21039 - DOI - PubMed
    1. Fardet L, Galicier L, Lambotte O, et al. . Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 2014;66:2613–20. 10.1002/art.38690 - DOI - PubMed
    1. Rivière S, Galicier L, Coppo P, et al. . Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am J Med 2014;127:1118–25. 10.1016/j.amjmed.2014.04.034 - DOI - PubMed
    1. Trottestam H, Horne A, Aricò M, et al. . Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood 2011;118:4577–84. 10.1182/blood-2011-06-356261 - DOI - PMC - PubMed

Publication types

MeSH terms

  NODES
admin 3
INTERN 4
twitter 2